Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vsResMed Inc (RMD)
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$2.43
-10.99%
HEALTHCARE · Cap: $7.59M
RMD
ResMed Inc
$196.04
+0.89%
HEALTHCARE · Cap: $28.25B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 11099898% more annual revenue ($5.54B vs $49,890). RMD leads profitability with a 27.4% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 73/100 (B).
CUPR
Avoid30
out of 100
Grade: F
RMD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CUPR.
Margin of Safety
-26.9%
Fair Value
$204.63
Current Price
$196.04
$8.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 267.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -92.4% — below average capital efficiency
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : CUPR
The strongest argument for CUPR centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 267.4% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : CUPR
The primary concerns for CUPR are EPS Growth, Market Cap, Profit Margin.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
CUPR profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.
CUPR is growing revenue faster at 267.4% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (73/100 vs 30/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?